ClinicalTrials.gg
Not yet recruitingNCT07334262Updated Jan 14, 2026

A Study to Evaluate the Food Effect on RNK08954 in Healthy Participants, and the Mass Balance Study of [14C]RNK08954 in Healthy Adult Male Subjects

A Phase 1 interventional study of RNK08954 in Food Effect and Mass Balance, sponsored by Ranok Therapeutics (Hangzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Ranok Therapeutics (Hangzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

An Study of Orally Administered RNK08954 in Healthy Adult Subjects to Determine the Effect of Food on the Pharmacokinetics of RNK08954,Mass Balance Study of [14C] RNK08954 in Chinese Healthy Adult Male Subjects

02

Conditions studied

  • Food Effect
  • Mass Balance
03

In context

Lead sponsor

Ranok Therapeutics (Hangzhou) Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, adult, male or female, 18-45 years of age, inclusive, at the screening visit.
  • Male participants must have a body weight of no less than 50 kg, and female participants must have a body weight of no less than 45 kg. The (BMI) should be between 19 and 26 kg/m² (inclusive).
  • Must follow protocol specified guidance.
  • Understands the study procedures in the form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  • abnormalities found in comprehensive physical examinations, vital signs, laboratory tests, 12-lead , chest X-ray, etc.
  • Positive results for surface antigen (HBsAg), virus antibody (HCV-Ab), antibody (HIV-Ab), or treponema pallidum antibody.
  • Individuals with allergic constitution.
  • Any history of clinically significant diseases or conditions that, in the investigator's judgment, may affect the trial results.
  • History or family history of organic heart disease, heart failure, myocardial infarction, angina pectoris, torsades de pointes, ventricular tachycardia, syndrome.
  • Gastrointestinal diseases that cause clinically significant symptoms such as nausea, vomiting, diarrhea, or malabsorption syndrome, or those with a history of vomiting or diarrhea within one week prior to screening.
  • Individuals with dysphagia.
  • Undergone major surgery within six months prior to the first dose or whose surgical incision has not fully healed.
  • Used drugs or received other experimental treatments within three months prior to the first dose or are currently participating in any other interventional clinical trials.
  • Vaccinated within one month prior to the first dose or plan to be vaccinated during the trial period.
  • Used any drugs affecting drug-metabolizing enzymes or transporters within 30 days prior to the first dose.
  • Taken any prescription drugs, over-the-counter medications, herbal medicines, or dietary supplements within 14 days prior to the first dose.
  • Smoke more than 10 cigarettes per day or habitually use nicotine-containing products within three months prior to the first dose.
  • Current or previous alcohol abuse, or frequent alcohol consumption within six months prior to the first dose, or those with a positive alcohol breath test.
  • History of drug abuse, use of soft drugs within three months prior to the first dose, or use of hard drugs within one year prior to the first dose, or those with a positive urine drug abuse screening.
  • Individuals who habitually or excessively consume grapefruit juice, tea, coffee, and/or caffeinated beverages.
  • History of blood loss or blood donation (≥400 mL) within three months prior to the first dose, those who have received blood transfusions or blood products within one month prior to the first dose, or those who plan to donate blood within three months after the trial.
  • Special dietary requirements, intolerance to high-fat meals, or inability to comply with a standardized diet.
  • History of needle or blood phobia, difficulty with blood collection, or intolerance to venipuncture.
  • Pregnant or lactating women.
  • have poor compliance or other factors that make them unsuitable for participation in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    RNK08954 Treatment A

    1200mg RNK08954, following an overnight fast of at least 10 hours

    Drug: RNK08954

  • Experimental
    RNK08954 Treatment B

    1200mg RNK08954, administered 30 minutes after the start of a high-fat/high-calorie meal breakfast.

    Drug: RNK08954

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma Pharmacokinetics (PK) of a single dose of RNK08954 after a standardized high-fat/high-calorie meal and after fasting: Tmax

    Time of Maximum concentration (Tmax)

    Time frame: 30 days

  2. Plasma Pharmacokinetics (PK) of a single dose of RNK08954 after a standardized high-fat/high-calorie meal and after fasting: Tlag

    absorption lag-time (Tlag)

    Time frame: 30 days

  3. Plasma Pharmacokinetics (PK) of a single dose of RNK08954 after a standardized high-fat/high-calorie meal and after fasting: Cmax

    Cmax for RNK08954 administered with and without food.

    Time frame: 30 days

  4. Plasma Pharmacokinetics (PK) of a single dose of RNK08954 after a standardized high-fat/high-calorie meal and after fasting: AUC0-inf

    Area under plasma Concentration (AUC) from zero to infinity

    Time frame: 30 days

  5. Plasma Pharmacokinetics (PK) of a single dose of RNK08954 after a standardized high-fat/high-calorie meal and after fasting: AUC0-last

    Area Under the concentration-time Curve from time zero to the time of the last

    Time frame: 30 days

Secondary outcomes

  1. Incidence,frequency and severity of adverse events (AEs)of RNK08954 as assessed by CTCAE 5.0

    As a measure of the safety and tolerability of RNK08954 the number of subjects who experienced any treatment emergent AE (TEAE), any causally related AE, any serious AE (SAE), and any causally related SAE are presented.

    Time frame: 30 days

  2. Electrocardiogram (ECG) parameters: HR, PR, QRS, QT, and QTc

    Safety and tolerability measures will be recorded at the indicated timepoints

    Time frame: 30 days

  3. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) (mmHG)

    Safety and tolerability measures will be recorded at the indicated timepoints

    Time frame: 30 days

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Jan 12, 2026
StartEst.
Dec 31, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07334262
Lead sponsor
Ranok Therapeutics (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Dec 31, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jan 14, 2026

Study contacts

Xin Wu
Contact
xinwu@ranoktherapeutics.com
86-0571-86630936

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RNK08954

Start the discussion